Peter Ljubenkov is a Neurology physician affiliated with University of California, San Francisco. OpenAlex indexes 84 publications with 1,793 citations (h-index 24); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
675 Nelson Rising Ln Ste 190
San Francisco, CA 941430003
Telephone
415-353-2057Provider last certified this registry record 16 Aug 2022.
Clinical trials
- Alzheimer's Tau Platform: Master Protocol
Sponsor: Paul S. Aisen
- Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Sponsor: Peter Ljubenkov, MD
- Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
Sponsor: Woolsey Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2026 per NIH RePORTER. The latest:
- Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2026$688,110R01AG073482 - Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2024$633,691R01AG073482 - Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
University of California, San Francisco
FY2023$638,870R01AG073482
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and neuropathological associations of plasma Aβ<sub>42</sub>/Aβ<sub>40</sub>, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
2025 - Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease
Neurology Clinical Practice
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”